Seeking editor for Clinical Liver Disease
23 February 2022
Reply
Ji Zhang, Tingting Zhao, Lai Wei, Yuzhang Wu – 23 February 2022
Development of a Robotic Shear Wave Elastography System for Noninvasive Staging of Liver Disease in Murine Models
Tomasz J. Czernuszewicz, Adam M. Aji, Christopher J. Moore, Stephanie A. Montgomery, Brian Velasco, Gabriela Torres, Keerthi S. Anand, Kennita A. Johnson, Allison M. Deal, Dženan Zukić, Matthew McCormick, Bernd Schnabl, Caterina M. Gallippi, Paul A. Dayton, Ryan C. Gessner – 23 February 2022 – Shear wave elastography (SWE) is an ultrasound‐based stiffness quantification technology that is used for noninvasive liver fibrosis assessment.
Hepatocelluar Carcinoma Risk in Advanced Fibrosis After Sustained Virologic Response: When Can We Safely Stop Hepatocellular Carcinoma Surveillance?
Masaru Enomoto, Philip Vutien, Norifumi Kawada – 23 February 2022
Letter to the editor: Beneath the surface of the pandemic: Persons with alcohol‐associated liver disease need our attention
Salah Kivlighn, Eric Schuur, Robert G. Gish, Donna Cryer – 23 February 2022
Issue Information
23 February 2022
LiverLearning®: 2022 Webinar: Going Beyond the Statement: Improving Diversity, Equity and Inclusion in Hepatology
The purpose of this webinar is to discuss action items for the AASLD and academic institutions. These action items will focus on efforts to improve diversity, equity and inclusion in all aspects of the hepatology continuum, including the hepatology work force as well as racial disparities in hepatology care. The webinar will include a formal 10-minute overview of the concepts of diversity, equity and inclusion and another 10-minute formal presentation on proposed future directions outlined in the white paper.
Intratumoral Microbiome of Human Primary Liver Cancer
Dingding Qu, Yi Wang, Qingxin Xia, Jing Chang, Xiangnan Jiang, He Zhang – 21 February 2022 – Primary liver tumors (PLCs) and liver metastasis currently represent the leading cause of cancer‐related deaths worldwide due to poor outcomes, high incidence, and postsurgical recurrence. Hence, novel diagnostic markers and therapeutic strategies for PLCs are urgently needed.
John R. Senior, MD
Mark Avigan, Paul B. Watkins – 21 February 2022
LiverLearning®: Fundamentals of Liver Disease - Alcohol-associated Liver Disease
DESCRIPTION The overall goal is to improve patient care by increasing learner competence and confidence in assessment and management of patients with alcohol-associated liver disease. The current content is geared towards increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved because of the improvements in more providers understanding these key components in the management and care of patients with alcohol-associated liver disease.